Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (5589)	9/18/1998 9:03:00 AM
From: Anthony Wong	Respond to of 9523

09/18 07:03 No evidence Viagra causes heart attacks - Pfizer LONDON, Sept 18 (Reuters) - U.S.-based drugs group Pfizer Inc <PFE.N> said on Friday there was no evidence that its impotence drug Viagra caused heart attacks or strokes. In response to a letter sent by doctors to the Lancet magazine outlining the case of a 65-year-old Dutch man who died 30 minutes after taking the drug, Pfizer said in a statement: "To date over three million men have been prescribed approximately 35 million Viagra tablets. This experience provides a consistent picture of the safety of Viagra when used appropriately." Pfizer noted the doctors writing in the Lancet stated it was unclear to what extent pre-existing coronary artery disease may have contributed to the onset of a heart attack in the patient. "An individual case documenting an adverse event with unclear associated medical information does not provide the basis for clinical conclusions," it said. The drug has been the subject of controversy in the U.S, where it has been linked to around 70 deaths since its launch in March. However, the company has said the incidence of deaths is no greater in those taking Viagra than in the target population generally. The unidentified man featured in the Lancet had been prescribed the drug while in the U.S, and died after taking it on the Caribbean island of Aruba. Viagra was approved for sale in the European Union on September 15.